How vaccines based on DNA origami work. (Photo = KIST)
[충남일보 김현수 기자] Dr. Joohee Ryu’s team at the Korea Institute of Science and Technology’s (KIST) Pharmaceutical Materials Research Center collaborated with Boston’s Dana-Farber Cancer Institute (DFCI) and Harvard’s Wyss Institute to develop a vaccine against cancer called “DoriVac” using DNA origami technology was developed.
DoriVac (DNA origami-based vaccine) is a next-generation cancer vaccine that precisely controls the spatial arrangement of CpG, an adjuvant, expanding the existing cancer vaccine strategy of simultaneously administering antigens and adjuvants.
To develop a cancer vaccine, the research team used DNA origami technology to place CpG, an immune enhancer, in an optimal spatial arrangement on the surface of a DNA nanostructure. DNA origami technology can create various shapes by folding DNA molecules like paper and can precisely control the structure even at the nanometer level (nm, one billionth of a meter). In this way, CpG molecules were precisely arranged at intervals between 2.5 and 7 nm on the surface of the DNA nanostructure, and cellular experiments demonstrated that the cancer immunotherapeutic effect was greatest at intervals of 3.5 nm. .
In animal experiments conducted by the research team, all but one of the five mice that developed skin cancer after being injected with “DoriVac” survived for up to 150 days, but all the mice that were not injected with anything they died on day 42, demonstrating that DoriVac is an aggressive agent and was confirmed to have a preventative effect in suppressing the growth of skin cancer cells.
Furthermore, when “Doribaek” containing 18 CpG molecules at 3.5 nm intervals was administered to mice in the early stages of skin cancer formation, it induced the most effective immune response and significantly suppressed tumor growth. This revealed that the therapeutic effect of cancer vaccines can be improved by precisely adjusting the spatial arrangement without increasing the amount of adjuvant.
This study is the result of joint research conducted since 2016 at the KIST-DFCI local laboratory located in Boston, United States, and was conducted based on KIST’s expertise in cancer treatment strategy technology and drug technology. DFCI DNA origami. The global joint research team co-founded “DoriNano Inc” in Boston and is pursuing clinical trials for the commercialization of “Dorivac” and is treating cancer and recurrences through combination with cancer treatment methods using other systems immune agents, such as immune checkpoint inhibitors are expected to increase the prevention effect.
Dr. Joohee Ryu’s team at the KIST Pharmaceutical Materials Research Center has developed an innovative cancer vaccine “DoriVac” using DNA origami nanostructures through joint research with the Dana-Farber Cancer Institute (DFCI) and others. (Photo = KIST)
Dr. Joohee Ryu from KIST said: “The development of Doribag is an important development that combines nanotechnology and cancer immunotherapy technology,” adding: “This will be a platform technology that can contribute to the development of ‘immunotherapy not only for the treatment of cancer but also for various diseases.’
The results of this research were published online in the latest issue of the international academic journal “Nature Nanotechnology”.
Send article to Facebook Send article to Twitter Send article to Kakao Story Send article to Kakao Talk Send article to Naver Band Send article to Naver Blog Send article to Pinterest ( Send article to Copy URL Send article to
Neighbor
#KISTDFCI #develops #cancer #vaccine #Doribaek.. #based #DNA #origami #technology
/cloudfront-ap-northeast-1.images.arcpublishing.com/chosun/S2IBXAOZBVBM5GTI637ZPC6ECM.gif?fit=300%2C300&ssl=1)
